LCK and HDAC1 may reduce T cells in SSc-PAH PBMCs through the regulation of T-cell activation, which suggest that these three molecules may be involved in the development of SSc-PAH. The gene discussed is HDAC1; the disease is pulmonary arterial hypertension.